Monthly Archives: June 2011

Everything you wanted to know about ghostwriting but were afraid to ask…

Share Two quick notes: the Project on Government Oversight (POGO) has posted a helpful FAQ on corporate-funded medical ghostwriting. As POGO investigator Paul Thacker writes: “We hope this [FAQ] will answer any questions you might have on this very disturbing … Continue reading

Posted in conflicts of interest, pharmaceutical industry | 1 Comment

The real reason biotech industry opposes Medicare advisory panel

Share A page-one story in The Boston Globe today spotlights the Massachusetts biotech industry’s effort to block a key piece of President Obama’s health care overhaul: the creation of an independent payment advisory board (IPAB) that would make recommendations on … Continue reading

Posted in biotech industry, conflicts of interest, drug marketing, health care costs, medical devices, pharmaceutical industry | 2 Comments

New Pfizer deal with Boston-area medical schools dissected on WGBH-TV

Share I was planning to blog about Pfizer’s new $100 million partnership with several Boston-area medical centers and its potential downsides. But before I could get around to doing that, I was invited to talk about the deal on WGBH-TV’s … Continue reading

Posted in pharmaceutical industry, Uncategorized, university industry collaboration | 1 Comment

Is the credibility of Emory neurologist Helen Mayberg in question? You judge

Share A few weeks ago, I blogged about the strange case of Dr. Helen Mayberg, a neurologist at Emory University who has testified in more death penalty cases in recent years than almost any other doctor in the country. I … Continue reading

Posted in antidepressants, conflicts of interest, expert testimony, medical devices, National Institutes of Health | 1 Comment